Abstract:AIM:To measure in parallel the serum levels and the peripheral blood mononuclear cell (PBMC) mRNA expression of IL-1β, IL-6 and TNF-α both before and after exposure to risperidone during a 4-week treatment protocol for schizophrenia, and to determine whether the levels of these factors were correlated with clinical variables. METHODS: ELISA and reverse transcription-polymerase chain reaction (RT-PCR) techniques were applied to analyze serum levels and PBMC mRNA expression of IL-1β, IL-6 and TNF-α in 83 schizophrenia patients and 65 healthy control subjects. RESULTS: ① Serum IL-1β, IL-6 and TNF-α levels in the schizophrenia group both pre- and post-treatment with risperidone were significantly higher than those in the control subjects (P<0.05). Serum IL-1β levels of the schizophrenia patients decreased significantly after 4-week treatment (P<0.05). ② Serum TNF-α levels of the negative subtype patients were significantly higher than those of the positive subtype patients before treatment (P<0.05). Serum IL-1β of the schizophrenia group and TNF-α levels of the negative subtype patients decreased significantly after 4-week treatment (P<0.05). Serum IL-6 levels of the familial schizophrenia were significantly higher than those of the sporadic schizophrenia before treatment (P<0.05). Serum IL-1β levels of the schizophrenia group and serum TNF-α levels of the familial schizophrenia decreased significantly after 4-week treatment (P<0.05). ③ There was significant correlation between the levels of TNF-α and the severity of negative symptom clusters evaluated by the PANSS (r=0.412, P<0.05). There was significant correlation between the difference of serum IL-1β levels pre- and post- treatment and the rate of the decreased PANSS (r=0.368, P<0.05). ④ IL-1β, IL-6 and TNF-α mRNA expression in the PBMC from the schizophrenia group both pre- and post-treatment were significantly higher than those from the control subjects (P<0.05). IL-1β mRNA expression in the PBMC from the schizophrenia patients decreased significantly after 4-week treatment (P<0.05). CONCLUSION: ① Schizophrenia patients are in a state of immune activation. The difference of serum IL-1β level between pre- and post-treatment with neuroleptic may be a sensitive parameter of illness recovery. ② Changes in the immune system are involved in the pathophy-siology of schizophrenia. ③ PBMC of schizophrenia patient is activated and may be one of major sources of cytokines.

Expression of retinoic acid receptor γ mRNA in blood leukocytes of acute schizophrenic patients

Imbalanced Free Radicals and Antioxidant Defense Systems in Schizophrenia: A Comparative Study

COMT, 5-HTR2A, and SLC6A4 Mrna Expressions in First-Episode Antipsychotic-Naïve Schizophrenia and Association with Treatment Outcomes

Expressional changes of neuregulin-1 gene mRNA in peripheral blood from schizophrenia patients]

Exploring the mRNA expression level of RELN in peripheral blood of schizophrenia patients before and after antipsychotic treatment

Expression of Dopamine D1−4 and Serotonin 5-HT1A-3A Receptors in Blood Mononuclear Cells in Schizophrenia

Serum protein and PBMC mRNA expressions of IL-1β, IL-6 and TNF-α in first-episode schizophrenia

Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients

Dysregulation of Retinoid Transporters Expression in Body Fluids of Schizophrenia Patients

An analysis of miR-195 in PBMC expression differences before and after antipsychotic treatment in pa-tients with schizophrenia

Study on serum levels, PBMC mRNA expression of IL-1β in first-episode schizophrenics

Verification of Proposed Peripheral Biomarkers in Mononuclear Cells of Individuals with Schizophrenia.

Explorative study on the expression of neuregulin-1 gene in peripheral blood of schizophrenia.

Dysregulated 14-3-3 Family in Peripheral Blood Leukocytes of Patients with Schizophrenia

Change of Expression of Dopamine Receptor D3 Gene Mrna in Peripheral Blood Lymphocytes in Childhood-First Onset Schizophrenia Before and after Treatment

Hematological and inflammatory markers in Han Chinese patients with drug-free schizophrenia: relationship with symptom severity

Neutrophil–Lymphocyte Ratio Values in Schizophrenia: A Comparison between Oral and Long-Acting Antipsychotic Therapies

Increased ratio of high sensitivity C-reactive protein to interleukin-10 as a potential peripheral biomarker of schizophrenia and aggression

Changes of Immune-Related Factors in the Blood of Schizophrenia and Bipolar Disorder Patients Receiving Monotherapy

Immune-inflammatory Markers in Schizophrenia: Comparison to Normal Controls and Effects of Clozapine.

Expression of GSK3β, PICK1, NEFL, C4, NKCC1 and Synaptophysin in Peripheral Blood Mononuclear Cells of the First-Episode Schizophrenia Patients.